Moorestown, New Jersey, United States

7322321334

seeking biotech alpha

seeking biotech alpha 寻求生物技术阿尔法 4/7/2020 the heart of biotech™

seeking biotech alpha 寻求生物技术阿尔法 4/7/2020 the heart of biotech™

seeking biotech alpha 寻求生物技术阿尔法 4/7/2020 the heart of biotech™ seeking biotech alpha 寻求生物技术阿尔法 4/7/2020 the heart of biotech™

seeking biotech alpha April 2019 insight

ViiV Healthcare, HIV-focused joint venture = GlaxoSmithKline (GSK), Pfizer (PFE) & Shionogi (SGIOY)

ViiV Healthcare, HIV-focused joint venture = GlaxoSmithKline (GSK), Pfizer (PFE) & Shionogi (SGIOY)

ViiV Healthcare, HIV-focused joint venture = GlaxoSmithKline (GSK), Pfizer (PFE) & Shionogi (SGIOY)

image312

ViiV Healthcare's Juluca shows sustained treatment effect in studies

Apr. 3, 2019 7:45 AM ET|About: GlaxoSmithKline plc (GSK)|By: , SA News Editor  

BriaCell Therapeutics (BCTXF) and Incyte (INCY)

ViiV Healthcare, HIV-focused joint venture = GlaxoSmithKline (GSK), Pfizer (PFE) & Shionogi (SGIOY)

ViiV Healthcare, HIV-focused joint venture = GlaxoSmithKline (GSK), Pfizer (PFE) & Shionogi (SGIOY)

image313

BriaCell Announces Clinical Trial Collaboration Agreement with Incyte

Tue April 2, 2019 2:58 PM|GlobeNewswire|About: BCTXF, INCY, MRK

  • BriaCell Therapeutics (BCTXF) and Incyte (INCY) have formed a non-exclusive clinical trial collaboration to evaluate the effects of combinations of novel clinical candidates
  • Under the agreement, Incyte will provide compounds from its development portfolio, including INCMGA0012, an anti-PD-1 monoclonal antibody, and epacadostat, an IDO1 inhibitor, for use in combination studies with BriaCell’s lead candidate, Bria-IMT™, in advanced breast cancer patients

BERKELEY, Calif., and VANCOUVER, British Columbia, April 02, 2019 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX-V:BCT) (OTCQB:BCTXF),

Editas Medicine and BlueRock Therapeutics Enter Strategic Research Collaboration

ViiV Healthcare, HIV-focused joint venture = GlaxoSmithKline (GSK), Pfizer (PFE) & Shionogi (SGIOY)

Editas Medicine and BlueRock Therapeutics Enter Strategic Research Collaboration

image314

 Editas Medicine and BlueRock Therapeutics Enter Strategic Research Collaboration and Cross-Licensing Agreement to Combine Genome Editing and Cell Therapy Platforms

Wed April 3, 2019 7:00 AM|GlobeNewswire|About: EDIT

– Collaboration enables BlueRock to discover and develop engineered cell medicines broadly across neurology, cardiology and immunology –

– Collaboration enables Editas Medicine (EDIT) to discover and develop engineered cell medicines across oncology, including solid tumors and blood cancers –

CAMBRIDGE, Mass., April 03, 2019 (GLOBE NEWSWIRE) -- Editas Medicine, Inc.,


 http://ir.editasmedicine.com/news-releases/news-release-details/editas-medicine-and-bluerock-therapeutics-enter-strategic 


 https://bluerocktx.com/  

VIZIMPRO® (dacomitinib)

Bria-IMT™ in combination with KEYTRUDA®

Editas Medicine and BlueRock Therapeutics Enter Strategic Research Collaboration

image315

 VIZIMPRO® (dacomitinib) Receives Marketing Authorization in European Union (EU) for the First-Line Treatment of Adult Patients with EGFR-Mutated Non-Small Cell Lung Cancer

Wed April 3, 2019 9:42 AM|Business Wire|About: PFE

NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (PFE)


 https://www.vizimpro.com/ 

Fasenra (benralizumab)

Bria-IMT™ in combination with KEYTRUDA®

Bria-IMT™ in combination with KEYTRUDA®

image317

AstraZeneca's Fasenra successful in mid-stage HES study

Apr. 4, 2019 7:21 AM ET|About: AstraZeneca PLC (AZN)|By: , SA News Editor  


 https://www.fasenra.com/ 

seeking biotech alpha April 2019 insight

combination of ipatasertib, Tecentriq (atezolizumab) & Abraxane (paclitaxel albumin-bound particles

combination of ipatasertib, Tecentriq (atezolizumab) & Abraxane (paclitaxel albumin-bound particles

combination of ipatasertib, Tecentriq (atezolizumab) & Abraxane (paclitaxel albumin-bound particles

image318

Roche's ipatasertib shows encouraging action in early-stage breast cancer study

Apr. 1, 2019 12:00 PM ET|About: Roche Holding AG (RHHBY)|By: , SA News Editor  


 https://www.tecentriq.com/ 

 https://www.abraxane.com/ 


intratumoral TLR9 agonist SD-101 induced a systemic anti-tumoral immune response

combination of ipatasertib, Tecentriq (atezolizumab) & Abraxane (paclitaxel albumin-bound particles

combination of ipatasertib, Tecentriq (atezolizumab) & Abraxane (paclitaxel albumin-bound particles

image319

Dynavax’s SD-101 and 4SC’s Domatinostat Demonstrate Synergy and Induce a Systemic Anti-tumor Response in Preclinical Models

Mon April 1, 2019 1:00 PM|GlobeNewswire|About: DVAX

BERKELEY, Calif. and PLANEGG-MARTINSRIED, Germany, April 01, 2019 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (DVAX)

Amgen Inc. (AMGN)

combination of ipatasertib, Tecentriq (atezolizumab) & Abraxane (paclitaxel albumin-bound particles

LOTEMAX® SM (loteprednol etabonate ophthalmic gel) 0.38%

image320

Amgen (AMGN) Presents At Oppenheimer's 29th Annual Healthcare Conference - Slideshow

Apr. 1, 2019 1:34 PM ET | About: Amgen Inc. (AMGN) 

LOTEMAX® SM (loteprednol etabonate ophthalmic gel) 0.38%

LOTEMAX® SM (loteprednol etabonate ophthalmic gel) 0.38%

LOTEMAX® SM (loteprednol etabonate ophthalmic gel) 0.38%

image321

Bausch + Lomb Announces The U.S. Launch Of LOTEMAX® SM (Loteprednol Etabonate Ophthalmic Gel) 0.38% For The Treatment Of Postoperative Inflammation And Pain Following Ocular Surgery

Tue April 2, 2019 7:00 AM|PR Newswire|About: BHC

Shipments to U.S. Pharmaceutical Distributors Begin

BRIDGEWATER, N.J., April 2, 2019 /PRNewswire

Johnson & Johnson (JNJ)

LOTEMAX® SM (loteprednol etabonate ophthalmic gel) 0.38%

Johnson & Johnson (JNJ)

image322

Johnson & Johnson Announces Completion of Acquisition of Auris Health, Inc.

Mon April 1, 2019 4:30 PM|PR Newswire|About: JNJPR Newswire

NEW BRUNSWICK, N.J., April 1, 2019 /PRNewswire/ -- Johnson & Johnson (JNJ) announced today that Ethicon, Inc., has completed the acquisition of Auris Health, Inc. for approximately $3.4 billion in cash.

Rubraca® (rucaparib)

LOTEMAX® SM (loteprednol etabonate ophthalmic gel) 0.38%

Johnson & Johnson (JNJ)

Clovis Oncology Announces Interim Results from Rubraca® (rucaparib) Phase 2 Study in Advanced Pancreatic Cancer and Nonclinical Data in Multiple Solid Tumor Types for Rucaparib and Lucitanib Presented at AACR 2019

Tue April 2, 2019 8:30 AM|Business Wire|About: CLVS 


 https://www.rubraca.com/ 


 https://ir.clovisoncology.com/investors-and-news/news-releases/press-release-details/2019/Clovis-Oncology-Announces-Interim-Results-from-Rubraca-rucaparib-Phase-2-Study-in-Advanced-Pancreatic-Cancer-and-Nonclinical-Data-in-Multiple-Solid-Tumor-Types-for-Rucaparib-and-Lucitanib-Presented-at-AACR-2019/default.aspx 

seeking biotech alpha April 2019 insight

KEYTRUDA® (pembrolizumab)

ALKS 3831 (olanzapine/samidorphan)

MEK 1/2 inhibitor selumetinib.

image323

Merck’s KEYTRUDA® (pembrolizumab) Approved in China for First-Line Treatment of Metastatic Nonsquamous Non-Small Cell Lung Cancer (NSCLC) in Combination with Chemotherapy

Mon April 1, 2019 6:55 AM|Business Wire|About: MRK

KEYTRUDA is First Anti-PD-1 Therapy to be Approved in Multiple Tumor Types in China

KENILWORTH, N.J.--(BUSINESS WIRE)-- Merck (MRK),

MEK 1/2 inhibitor selumetinib.

ALKS 3831 (olanzapine/samidorphan)

MEK 1/2 inhibitor selumetinib.

image324

Selumetinib Granted U.S. Breakthrough Therapy Designation in Neurofibromatosis Type 1

Mon April 1, 2019 6:30 AM|Business Wire|About: MRK

Designation Based on Phase 2 SPRINT Trial in Pediatric Patients with NF1 Plexiform Neurofibromas

Selumetinib Is a MEK 1/2 Inhibitor Being Co-Developed by AstraZeneca and Merck (MRK)

KENILWORTH, N.J.--(BUSINESS WIRE)-- AstraZeneca and Merck


ALKS 3831 (olanzapine/samidorphan)

ALKS 3831 (olanzapine/samidorphan)

Bausch Health Companies Inc. (BHC) and UCLA's Technology Development Group

image325

Alkermes to Present New ALKS 3831 Data From ENLIGHTEN-2 and Interim Extension Safety Study Results at 2019 Congress of the Schizophrenia International Research Society

  • Mon April 1, 2019 7:00 AM|PR Newswire|About: ALKS
  • -- Poster Presentations to Highlight New Data on ARISTADA® and ALKS 3831 --

PR Newswire

DUBLIN, April 1, 2019 /PRNewswire/ -- Alkermes plc (ALKS

Bausch Health Companies Inc. (BHC) and UCLA's Technology Development Group

ADXS-PSA, Listeria monocytogenes (Lm)-based immunotherapies, with KEYTRUDA® (pembrolizumab)

Bausch Health Companies Inc. (BHC) and UCLA's Technology Development Group

Salix Enters Into License Agreement With The University Of California To Develop And Commercialize Novel Compound For The Treatment Of Non-alcoholic Fatty Liver Disease And Non-alcoholic Steatohepatitis

Mon April 1, 2019 7:00 AM|PR Newswire|About: BHC

Investigational Treatment Demonstrated Promising Results in Preclinical Studies

BRIDGEWATER, N.J., April 1, 2019 /PRNewswire/

ADXS-PSA, Listeria monocytogenes (Lm)-based immunotherapies, with KEYTRUDA® (pembrolizumab)

ADXS-PSA, Listeria monocytogenes (Lm)-based immunotherapies, with KEYTRUDA® (pembrolizumab)

ADXS-PSA, Listeria monocytogenes (Lm)-based immunotherapies, with KEYTRUDA® (pembrolizumab)

image326

ADXS-PSA in Combination with KEYTRUDA® Prolonged Survival in Metastatic Castration-Resistant Prostate Cancer

Mon April 1, 2019 8:00 AM|Business Wire|About: ADXS

Updated Results from Phase 1/2 Study to be Presented Today at the AACR Annual Meeting

PRINCETON, N.J.--(BUSINESS WIRE)-- Advaxis, Inc. (ADXS)


 https://www.advaxis.com/clinical-trials/ 

investigational subcutaneous (SC) formulation of vedolizumab -Entyvio® (vedolizumab)

ADXS-PSA, Listeria monocytogenes (Lm)-based immunotherapies, with KEYTRUDA® (pembrolizumab)

ADXS-PSA, Listeria monocytogenes (Lm)-based immunotherapies, with KEYTRUDA® (pembrolizumab)

image327

European Medicines Agency Accepts Takeda’s Marketing Authorization Application for a Subcutaneous Formulation of Vedolizumab for Maintenance Therapy in Moderately to Severely Active Ulcerative Colitis and Crohn’s Disease

April 1, 2019 Osaka, JAPAN

  • Additional treatment modality would provide greater choice in how patients receive gut-selective biologic vedolizumab
  • Vedolizumab set to be the only maintenance therapy to offer the option of intravenous or subcutaneous formulations across ulcerative colitis and Crohn’s disease

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”)

seeking biotech alpha March 2019 insight

ZYNTEGLO™ (autologous CD34+ cells encoding β A-T87Q-globin gene)

tisotumab vedotin as monotherapy for patients with recurrent and/or metastatic cervical cancer

tisotumab vedotin as monotherapy for patients with recurrent and/or metastatic cervical cancer

image328

bluebird bio Receives Positive Opinion from CHMP for ZYNTEGLO™ (autologous CD34+ cells encoding βA-T87Q-globin gene) Gene Therapy for Patients 12 Years and Older with Transfusion-Dependent β-Thalassemia (TDT) Who Do Not Have β0/β0 Genotype

Fri March 29, 2019 7:44 AM|Business Wire|About: BLUE 


 https://www.bluebirdbio.com/research-development/pipeline/ 

tisotumab vedotin as monotherapy for patients with recurrent and/or metastatic cervical cancer

tisotumab vedotin as monotherapy for patients with recurrent and/or metastatic cervical cancer

tisotumab vedotin as monotherapy for patients with recurrent and/or metastatic cervical cancer

image329

Seattle Genetics Completes Enrollment in Phase 2 Clinical Trial of Tisotumab Vedotin in Recurrent or Metastatic Cervical Cancer

Fri March 29, 2019 8:00 AM|Business Wire|About: SGEN

-Phase 2 innovaTV 204 Trial Designed to Support Potential Accelerated Approval Pathway in U.S.-

BOTHELL, Wash.--(BUSINESS WIRE)-- Seattle Genetics, Inc. (SGEN) (Nasdaq:SGEN) 


 http://www.seattlegenetics.com/pipeline/tisotumab-vedotin 


 http://www.genmab.com/product-pipeline/products-in-development/humax-tf-adc 

Viking Therapeutics, Inc. (VKTX)

Bristol-Myers Squibb's (BMY) $74B takeover of Celgene (CELG)

REVLIMID (lenalidomide) and IMNOVID (pomalidomide).

image331

Viking Therapeutics to Participate in Upcoming Investor Conferences

Thu March 28, 2019 7:30 AM|PR Newswire|About: VKTX

SAN DIEGO, March 28, 2019 /PRNewswire/ -- Viking Therapeutics, Inc. (VKTX

Mozobil (plerixafor injection)

Bristol-Myers Squibb's (BMY) $74B takeover of Celgene (CELG)

Bristol-Myers Squibb's (BMY) $74B takeover of Celgene (CELG)

image332

European advisory group backs expanded use of Sanofi's Mozobil

Mar. 29, 2019 8:32 AM ET|About: Sanofi (SNY)|By: , SA News Editor 

Bristol-Myers Squibb's (BMY) $74B takeover of Celgene (CELG)

Bristol-Myers Squibb's (BMY) $74B takeover of Celgene (CELG)

Bristol-Myers Squibb's (BMY) $74B takeover of Celgene (CELG)

image333

 Starboard pulls out of Celgene fight

Mar. 29, 2019 12:22 PM ET|About: Bristol-Myers Squibb C... (BMY)|By: , SA News Editor  

seeking biotech alpha March 2019 insight

filgotinib, an investigational, oral, selective JAK1 inhibitor

VY-AADC, an investigational gene therapy treatment for Parkinson’s disease

VY-AADC, an investigational gene therapy treatment for Parkinson’s disease

image334

Gilead and Galapagos Announce Filgotinib Meets Primary Endpoint in the Phase 3 FINCH 3 Study in Methotrexate-Naïve Rheumatoid Arthritis Patients

Thu March 28, 2019 5:04 PM|Business Wire|About: GILD, GLPG 

VY-AADC, an investigational gene therapy treatment for Parkinson’s disease

VY-AADC, an investigational gene therapy treatment for Parkinson’s disease

VY-AADC, an investigational gene therapy treatment for Parkinson’s disease

image335

Neurocrine Biosciences and Voyager Therapeutics Announce Publication of Phase 1b Trial Results of VY-AADC for Parkinson’s Disease in the Annals of Neurology

Thu March 28, 2019 4:15 PM|GlobeNewswire|About: NBIX, VYGR

SAN DIEGO and CAMBRIDGE, Mass., March 28, 2019 (GLOBE NEWSWIRE) -- Neurocrine Biosciences, Inc. (NBIX) and Voyager Therapeutics, Inc. (VYGR


 Voyager Therapeutics, Inc. (VYGR)  

 https://www.voyagertherapeutics.com/  

HEPLISAV-B [Hepatitis B Vaccine, Recombinant (Adjuvanted)]

VY-AADC, an investigational gene therapy treatment for Parkinson’s disease

Mayzent® (siponimod) for the treatment of adults with relapsing forms of multiple sclerosis

image336

Dynavax Announces European Medicines Agency Accepts Marketing Authorization Application for HEPLISAV-B® for Prevention of Hepatitis B in Adults

Thu March 28, 2019 4:05 PM|GlobeNewswire|About: DVAX

BERKELEY, Calif., March 28, 2019 (GLOBE NEWSWIRE) -- Dynavax Technologies Corporation (DVAX)


 http://www.dynavax.com/our-pipeline/ 

Mayzent® (siponimod) for the treatment of adults with relapsing forms of multiple sclerosis

Mayzent® (siponimod) for the treatment of adults with relapsing forms of multiple sclerosis

Mayzent® (siponimod) for the treatment of adults with relapsing forms of multiple sclerosis

image337

 Basel, March 27, 2019   Novartis receives FDA approval for Mayzent® (siponimod), the first oral drug to treat secondary progressive MS with active disease

Mar 27, 2019

  • Mayzent® (siponimod) is the first and only treatment specifically approved for patients with active secondary progressive multiple sclerosis (SPMS) in over 15 years[1]
     
  • Up to 80% of patients with relapsing remitting MS (RRMS) will develop SPMS[2]; Mayzent addresses a critical unmet need for RRMS patients in transition and those with active SPMS who have transitioned 
     
  • Approval is based on the Phase III EXPAND trial, the largest controlled clinical study of SPMS patients, showing Mayzent significantly reduced the risk of disease progression, including impact on physical disability and cognitive decline[3]
     
  • Mayzent is approved across the MS spectrum for clinically isolated syndrome (CIS), RRMS and active SPMS, with most patients not requiring a first dose observation

AstraZeneca is spearheading the creation of a new life sciences park, in Wuxi, China

Mayzent® (siponimod) for the treatment of adults with relapsing forms of multiple sclerosis

AstraZeneca is spearheading the creation of a new life sciences park, in Wuxi, China

image338

AstraZeneca leads in the development of a new International Life Science Innovation Park in China

PUBLISHED27 March 2019 


 Cluster to be built by the Wuxi municipal government and Wuxi High-tech District

AstraZeneca PLC (AZN) & Daiichi Sankyo's (OTCPK:DSNKY)

Mayzent® (siponimod) for the treatment of adults with relapsing forms of multiple sclerosis

AstraZeneca is spearheading the creation of a new life sciences park, in Wuxi, China

image339

AstraZeneca, Daiichi Sankyo ink $6.9B cancer deal

Mar. 29, 2019 3:33 AM ET|About: AstraZeneca PLC (AZN)|By: , SA News Editor 


 https://www.daiichisankyo.com/rd/pipeline/pdf/20190131_Pipeline_EN.pdf  


 Bolstering its oncology push, AstraZeneca (NYSE:AZN) has struck a deal worth up to $6.9B to sell and develop Daiichi Sankyo's (OTCPK:DSNKY) promising new cancer drug. 

seeking biotech alpha March 2019 insight

DARZALEX (daratumumab)

35 Abstracts Across NASH, PSC and Viral Hepatitis Commitment to Advancing Liver Disease Research

35 Abstracts Across NASH, PSC and Viral Hepatitis Commitment to Advancing Liver Disease Research

image340

 Janssen Submits Application for DARZALEX® (daratumumab) Combination Therapy to U.S. FDA for Newly Diagnosed, Transplant Eligible Patients with Multiple Myeloma

First DARZALEX combination treatment regimen being pursued in the frontline setting for transplant eligible patients with multiple myeloma

RARITAN, NJ, March 26, 2019 – The Janssen Pharmaceutical Companies of Johnson & Johnson

35 Abstracts Across NASH, PSC and Viral Hepatitis Commitment to Advancing Liver Disease Research

35 Abstracts Across NASH, PSC and Viral Hepatitis Commitment to Advancing Liver Disease Research

35 Abstracts Across NASH, PSC and Viral Hepatitis Commitment to Advancing Liver Disease Research

image341

Gilead to Present New Data From Multiple Liver Disease Research and Development Programs at The International Liver Congress™ 2019

Wed March 27, 2019 6:06 AM|Business Wire|About: GILD 

ACUVUE OASYS with TRANSITIONS LIGHT INTELLIGENT TECHNOLOGY

35 Abstracts Across NASH, PSC and Viral Hepatitis Commitment to Advancing Liver Disease Research

ACUVUE OASYS with TRANSITIONS LIGHT INTELLIGENT TECHNOLOGY

image342

Johnson & Johnson Vision Announces Availability of ACUVUE OASYS with TRANSITIONS LIGHT INTELLIGENT TECHNOLOGY in the U.S.

Wed March 27, 2019 4:49 PM|PR Newswire|About: JNJPR Newswire

JACKSONVILLE, Fla., March 27, 2019 /PRNewswire/ -- Johnson & Johnson Vision 

Casimersen (SRP-4045)

Seattle Genetics and Astellas reports positive data from EV-201

ACUVUE OASYS with TRANSITIONS LIGHT INTELLIGENT TECHNOLOGY

image343

Sarepta Therapeutics Announces Positive Expression Results from the Casimersen (SRP-4045) Arm of the ESSENCE Study

Thu March 28, 2019 8:30 AM|GlobeNewswire|About: SRPT 

INVOKANA® (canagliflozin)

Seattle Genetics and Astellas reports positive data from EV-201

Seattle Genetics and Astellas reports positive data from EV-201

image344

 Janssen Submits Supplemental New Drug Application to U.S. FDA for INVOKANA®(canagliflozin) for the Treatment of Chronic Kidney Disease in Patients with Type 2 Diabetes

If approved, INVOKANA® will be the first and only therapy in nearly 20 years indicated to reduce the risk of end-stage kidney disease when added to current standard of care

Submission is based on data from the landmark Phase 3 CREDENCE renal outcomes study, which stopped early for positive efficacy findings

Raritan, N.J., March 28, 2019 

Seattle Genetics and Astellas reports positive data from EV-201

Seattle Genetics and Astellas reports positive data from EV-201

Seattle Genetics and Astellas reports positive data from EV-201

image345

Seattle Genetics to Host Conference Call on Positive Topline Results from Pivotal Trial of Enfortumab Vedotin

Thu March 28, 2019 7:00 AM|Business Wire|About: SGEN

BOTHELL, Wash.--(BUSINESS WIRE)-- Seattle Genetics, Inc. (SGEN)


 http://www.seattlegenetics.com/pipeline/enfortumab-vedotin 


 https://seekingalpha.com/pr/17457684-seattle-genetics-astellas-announce-positive-topline-results-pivotal-trial-enfortumab-vedotin 

seeking biotech alpha March 2019 insight

Biktarvy® (bictegravir 50mg/emtricitabine 200mg/tenofovir alafenamide 25mg, BIC/FTC/TAF)

Illumina (ILMN) & Lundbeck Foundation GeoGenetics Centre at the University of Copenhagen, Denmark

Illumina (ILMN) & Lundbeck Foundation GeoGenetics Centre at the University of Copenhagen, Denmark

image346

Japan’s Ministry of Health, Labour and Welfare Approves Gilead’s Biktarvy® (Bictegravir, Emtricitabine and Tenofovir Alafenamide) for Treatment of HIV-1 Infection

Tue March 26, 2019 8:30 AM|Business Wire|About: GILD 


 https://www.biktarvy.com/ 

Illumina (ILMN) & Lundbeck Foundation GeoGenetics Centre at the University of Copenhagen, Denmark

Illumina (ILMN) & Lundbeck Foundation GeoGenetics Centre at the University of Copenhagen, Denmark

Illumina (ILMN) & Lundbeck Foundation GeoGenetics Centre at the University of Copenhagen, Denmark

image347

Illumina and the Lundbeck Foundation GeoGenetics Centre Collaborate to Generate One of the Largest Ancient Genome Datasets to Decode the Genetic Origins and Evolution of Mental Health Issues

Tue March 26, 2019 2:00 AM|Business Wire|About: ILMN 

Allergan plc (AGN) today announced it has completed the acquisition of Envy Medical, Inc.,

Illumina (ILMN) & Lundbeck Foundation GeoGenetics Centre at the University of Copenhagen, Denmark

Allergan plc (AGN) today announced it has completed the acquisition of Envy Medical, Inc.,

image348

Allergan Acquires Envy Medical, Inc., Adding Skin Resurfacing Dermalinfusion System to Best-in-Class Medical Aesthetics Portfolio

Tue March 26, 2019 9:00 AM|PR Newswire|About: AGNPR Newswire

DUBLIN, March 26, 2019 /PRNewswire/ -- Allergan plc (AGN)

(etafilcon A with 0.019 mg ketotifen)

Afirma® Xpression Atlas suggest that the majority of newly diagnosed medullary thyroid cancers (MTC)

Allergan plc (AGN) today announced it has completed the acquisition of Envy Medical, Inc.,

image349

Johnson & Johnson Vision's Investigational Antihistamine-Releasing Contact Lens Demonstrates Positive Phase 3 Results

Tue March 26, 2019 8:00 AM|PR Newswire|About: JNJPR Newswire

JACKSONVILLE, Fla., March 26, 2019 /PRNewswire/ -- Johnson & Johnson 

Afirma® Xpression Atlas suggest that the majority of newly diagnosed medullary thyroid cancers (MTC)

Afirma® Xpression Atlas suggest that the majority of newly diagnosed medullary thyroid cancers (MTC)

Afirma® Xpression Atlas suggest that the majority of newly diagnosed medullary thyroid cancers (MTC)

image350

Veracyte Announces New Afirma Xpression Atlas Data that Advance Genomic Understanding of Medullary Thyroid Cancer

Mon March 25, 2019 4:15 PM|Business Wire|About: VCYT 


 https://www.veracyte.com/our-products 

oral semaglutide 3 mg, 7 mg and 14 mg

Afirma® Xpression Atlas suggest that the majority of newly diagnosed medullary thyroid cancers (MTC)

Afirma® Xpression Atlas suggest that the majority of newly diagnosed medullary thyroid cancers (MTC)

image351

Oral semaglutide 7 mg and 14 mg doses showed superior reductions in blood sugar and weight compared to sitagliptin at 26 weeks in data presented at ENDO

Sat March 23, 2019 2:00 PM|PR Newswire|About: NONOF, NVO

NEW ORLEANS, March 23, 2019 /PRNewswire/ 

seeking biotech alpha March 2019 insight

anti-amyloid beta protofibril monoclonal antibody BAN2401 in patients w/early Alzheimer's disease

anti-amyloid beta protofibril monoclonal antibody BAN2401 in patients w/early Alzheimer's disease

anti-amyloid beta protofibril monoclonal antibody BAN2401 in patients w/early Alzheimer's disease

image352

 Biogen and Eisai launch late-stage study of BAN2401 in Alzheimer's

Mar. 22, 2019 9:12 AM ET|About: Biogen Inc. (BIIB)|By: , SA News Editor  

Forxiga (dapagliflozin) for patients with type 1 diabetes (T1D)

anti-amyloid beta protofibril monoclonal antibody BAN2401 in patients w/early Alzheimer's disease

anti-amyloid beta protofibril monoclonal antibody BAN2401 in patients w/early Alzheimer's disease

image353

AstraZeneca's Forxiga OK'd in Europe for T1D

Mar. 25, 2019 7:04 AM ET|About: AstraZeneca PLC (AZN)|By: , SA News Editor  


 https://www.farxiga.com/ 

Ozanimod is an oral, sphingosine 1-phosphate (S1P) receptor modulator

anti-amyloid beta protofibril monoclonal antibody BAN2401 in patients w/early Alzheimer's disease

Ozanimod is an oral, sphingosine 1-phosphate (S1P) receptor modulator

image354

Celgene Submits Application to FDA for Ozanimod for the Treatment of Relapsing Forms of Multiple Sclerosis

Mon March 25, 2019 4:30 PM|Business Wire|About: CELG

SUMMIT, N.J.--(BUSINESS WIRE)-- Celgene Corporation (CELG)

SKYRIZI™ (risankizumab), an interleukin-23 (IL-23) inhibitor

SKYRIZI™ (risankizumab), an interleukin-23 (IL-23) inhibitor

Ozanimod is an oral, sphingosine 1-phosphate (S1P) receptor modulator

image355

AbbVie Announces First Regulatory Approval of SKYRIZI™ (risankizumab) for the Treatment of Plaque Psoriasis, Generalized Pustular Psoriasis and Erythrodermic Psoriasis and Psoriatic Arthritis in Japan

Tue March 26, 2019 1:00 AM|PR Newswire|About: ABBV 

Bria-IMT™, with KEYTRUDA®

SKYRIZI™ (risankizumab), an interleukin-23 (IL-23) inhibitor

Bria-IMT™, with KEYTRUDA®

image356

BriaCell to Announce Early Efficacy Data of Lead Candidate in Combination with KEYTRUDA® at AACR Annual Meeting

Tue March 26, 2019 6:30 AM|GlobeNewswire|About: BCTXF, MRK 


 https://www.merck.com/product/usa/pi_circulars/k/keytruda/keytruda_pi.pdf 

TriGrid® Delivery System.

SKYRIZI™ (risankizumab), an interleukin-23 (IL-23) inhibitor

Bria-IMT™, with KEYTRUDA®

image357

Ichor Medical Systems Announces Collaboration and Research License Agreement with AstraZeneca to Develop DNA-based Monoclonal Antibody Platform

Tue March 26, 2019 7:00 AM|Business Wire|About: AZN

SAN DIEGO--(BUSINESS WIRE)-- Ichor® Medical Systems, Inc. (Ichor) 


 TriGrid® Delivery System


seeking biotech alpha March 2019 insight

MAVIRET™ (glecaprevir/pibrentasvir tablets)

DARZALEX (daratumumab), combined w/Celgene's (CELG) REVLIMID (lenalidomide)&dexamethasone

DARZALEX (daratumumab), combined w/Celgene's (CELG) REVLIMID (lenalidomide)&dexamethasone

image358

 British Columbia PharmaCare Lists AbbVie's Hepatitis C Treatment MAVIRET™ on its Formulary

Fri March 22, 2019 10:29 AM|Canada Newswire|About: ABBV 

DARZALEX (daratumumab), combined w/Celgene's (CELG) REVLIMID (lenalidomide)&dexamethasone

DARZALEX (daratumumab), combined w/Celgene's (CELG) REVLIMID (lenalidomide)&dexamethasone

DARZALEX (daratumumab), combined w/Celgene's (CELG) REVLIMID (lenalidomide)&dexamethasone

image359

J&J files European marketing application for expanded use of Darzalex

Mar. 22, 2019 8:22 AM ET|About: Celgene Corporation (CELG)|By: , SA News Editor 

Thermo Fisher will acquire Brammer Bio for approximately $1.7 billion in cash.

DARZALEX (daratumumab), combined w/Celgene's (CELG) REVLIMID (lenalidomide)&dexamethasone

Phase 1 study of Sarepta’s micro-dystrophin gene therapy candidate for Duchenne muscular dystrophy

image360

 Thermo Fisher Scientific to Acquire Brammer Bio, a Leader in Viral Vector Manufacturing

Sun March 24, 2019 8:30 PM|PR Newswire|About: TMO

Phase 1 study of Sarepta’s micro-dystrophin gene therapy candidate for Duchenne muscular dystrophy

Phase 1 study of Sarepta’s micro-dystrophin gene therapy candidate for Duchenne muscular dystrophy

Phase 1 study of Sarepta’s micro-dystrophin gene therapy candidate for Duchenne muscular dystrophy

image361

Sarepta Therapeutics to Provide Update on Duchenne Muscular Dystrophy Gene Therapy Program

Mon March 25, 2019 7:30 AM|GlobeNewswire|About: SRPT 

Providence Cancer Institute and Galectin Therapeutics Inc. (GALT)

Phase 1 study of Sarepta’s micro-dystrophin gene therapy candidate for Duchenne muscular dystrophy

bb2121 and bb21217 for the treatment of multiple myeloma and potentially LentiGlobin™

image362

Providence Cancer Institute to Present Findings on GR-MD-02 at the 2019 Keystone Symposia on Molecular and Cellular Biology

Fri March 22, 2019 10:19 AM|GlobeNewswire|About: GALT

NORCROSS, Ga., March 22, 2019 (GLOBE NEWSWIRE) -- Providence Cancer Institute and Galectin Therapeutics Inc. (GALT)

bb2121 and bb21217 for the treatment of multiple myeloma and potentially LentiGlobin™

Phase 1 study of Sarepta’s micro-dystrophin gene therapy candidate for Duchenne muscular dystrophy

bb2121 and bb21217 for the treatment of multiple myeloma and potentially LentiGlobin™

image363

bluebird bio Opens State-of-the-Art Gene and Cell Therapy Manufacturing Facility in Durham, North Carolina

Fri March 22, 2019 8:00 AM|Business Wire|About: BLUE 

seeking biotech alpha March 2019 insight

Phase IIa combination study of Bria-IMT™ with KEYTRUDA® [ Merck (MRK)] in advanced breast cancer

ABIOMED (NASDAQ:ABMD) discloses a 6% stake of 1,678,843 shares in ShockWave Medical (NASDAQ:SWAV),

Phase IIa combination study of Bria-IMT™ with KEYTRUDA® [ Merck (MRK)] in advanced breast cancer

image364

BriaCell Announces $2,000,000 Non-Brokered Private Placement Offering

Wed March 20, 2019 4:05 PM|GlobeNewswire|About: BCTXF, MRK

BERKELEY, Calif. and VANCOUVER, British Columbia, March 20, 2019 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (BCTXF) ("BriaCell" or the "Company") (TSX-V:BCT) (OTCQB:BCTXF)

Novocure (NVCR) on Tumor Treating Fields at the American Association for Cancer Research (AACR)

ABIOMED (NASDAQ:ABMD) discloses a 6% stake of 1,678,843 shares in ShockWave Medical (NASDAQ:SWAV),

Phase IIa combination study of Bria-IMT™ with KEYTRUDA® [ Merck (MRK)] in advanced breast cancer

image365

Novocure Announces 48 Presentations and a Symposium Session on Tumor Treating Fields at the American Association for Cancer Research Annual Meeting 2019

Thu March 21, 2019 7:30 AM|Business Wire|About: NVCR 

ABIOMED (NASDAQ:ABMD) discloses a 6% stake of 1,678,843 shares in ShockWave Medical (NASDAQ:SWAV),

ABIOMED (NASDAQ:ABMD) discloses a 6% stake of 1,678,843 shares in ShockWave Medical (NASDAQ:SWAV),

ABIOMED (NASDAQ:ABMD) discloses a 6% stake of 1,678,843 shares in ShockWave Medical (NASDAQ:SWAV),

Abiomed reports 6% stake in ShockWave Medical

Mar. 21, 2019 6:55 AM ET|About: ABIOMED, Inc. (ABMD)|By: , SA News Editor  


https://shockwavemedical.com/?country=United%20States

Viking Therapeutics, Inc. (VKTX)

INNOVATE-3, a phase 3 pivotal trial testing the efficacy of Tumor Treating Fields with paclitaxel

ABIOMED (NASDAQ:ABMD) discloses a 6% stake of 1,678,843 shares in ShockWave Medical (NASDAQ:SWAV),

image366

Viking Therapeutics (VKTX) Investor Presentation - Slideshow

Mar. 21, 2019 3:12 PM ET | About: Viking Therapeutics, Inc. (VKTX) 

Sorrento Therapeutics, Inc. (SRNE)

INNOVATE-3, a phase 3 pivotal trial testing the efficacy of Tumor Treating Fields with paclitaxel

INNOVATE-3, a phase 3 pivotal trial testing the efficacy of Tumor Treating Fields with paclitaxel

image367

Sorrento Therapeutics (SRNE) Presents At Oppenheimer 29th Annual Healthcare Conference - Slideshow

Mar. 21, 2019 2:29 PM ET|1 comment | About: Sorrento Therapeutics, Inc. (SRNE) 

INNOVATE-3, a phase 3 pivotal trial testing the efficacy of Tumor Treating Fields with paclitaxel

INNOVATE-3, a phase 3 pivotal trial testing the efficacy of Tumor Treating Fields with paclitaxel

INNOVATE-3, a phase 3 pivotal trial testing the efficacy of Tumor Treating Fields with paclitaxel

Novocure Initiates Phase 3 Pivotal Trial in Recurrent Ovarian Cancer

Fri March 22, 2019 7:30 AM|Business Wire|About: NVCR

INNOVATE-3


https://www.novocure.com/novocure-initiates-phase-3-pivotal-trial-in-recurrent-ovarian-cancer/

seeking biotech alpha March 2019 insight

Pfizer acquires 15% ownership stake in Vivet

oral semaglutide, a once-daily glucagon-like peptide-1 (GLP-1) receptor agonist in pill form.

Merck (MRK) to Return GDF15 Receptor Agonist Program to NGM

Pfizer Secures Exclusive Option to Acquire Gene Therapy Company Vivet Therapeutics

Wed March 20, 2019 6:45 AM|Business Wire|About: PFE 

Merck (MRK) to Return GDF15 Receptor Agonist Program to NGM

oral semaglutide, a once-daily glucagon-like peptide-1 (GLP-1) receptor agonist in pill form.

Merck (MRK) to Return GDF15 Receptor Agonist Program to NGM

image368

Merck and NGM Bio Announce Extension of Broad, Multi-Year Strategic Collaboration to 2022

Wed March 20, 2019 6:30 AM|Business Wire|About: MRK 

oral semaglutide, a once-daily glucagon-like peptide-1 (GLP-1) receptor agonist in pill form.

oral semaglutide, a once-daily glucagon-like peptide-1 (GLP-1) receptor agonist in pill form.

Alexion Pharmaceuticals, Inc. (ALXN) (NASDAQ:ALXN) and Affibody AB today announced a partnership

image369

Novo files two U.S. applications for oral semaglutide

Mar. 20, 2019 11:07 AM ET|About: Novo Nordisk A/S (NVO)|By: , SA News Editor  

The National Comprehensive Cancer Network® (NCCN®) Oncology Research Program (ORP) & Eli Lilly (LLY)

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) and Zealand Pharma A/S (ZEAL) announced a collaboration

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) and Zealand Pharma A/S (ZEAL) announced a collaboration

image371

NCCN Announces Six Quality Improvement Projects in Gastric Cancer Care Approved for Collaboration with Lilly Oncology

Wed March 20, 2019 8:45 AM|PR Newswire|About: LLY

PLYMOUTH MEETING, Pa. and INDIANAPOLIS, March 20, 2019 /PRNewswire/ -- The National Comprehensive Cancer Network® (NCCN®) Oncology Research Program (ORP) and Eli Lilly and Company (LLY

seeking biotech alpha March 2019 insight

AVYCAZ® (ceftazidime and avibactam)

KEYTRUDA® (pembrolizumab) in Combination with Pemetrexed and Platinum Chemotherapy

AVYCAZ® (ceftazidime and avibactam)

image373

Allergan Announces FDA Approval of AVYCAZ® (ceftazidime and avibactam) for Pediatric Patients

- Label Now Includes New Data on Use of AVYCAZ for Treatment of cUTI and cIAI in Pediatric Patients 3 Months of Age and Older -

DUBLIN, March 18, 2019 /PRNewswire/ -- Allergan plc (NYSE: AGN

KEYTRUDA® (pembrolizumab) in Combination with Pemetrexed and Platinum Chemotherapy

KEYTRUDA® (pembrolizumab) in Combination with Pemetrexed and Platinum Chemotherapy

KEYTRUDA® (pembrolizumab) in Combination with Pemetrexed and Platinum Chemotherapy

image374

 New Treatment Option Now Available in Canada for Newly Diagnosed Patients with Advanced Lung Cancer

Mon March 18, 2019 8:00 AM|Canada Newswire|About: MRK 


https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/notice-compliance/conditions.html

Data demonstrates survival benefit with the Impella RP Recover Right protocol

Data demonstrates survival benefit with the Impella RP Recover Right protocol

Data demonstrates survival benefit with the Impella RP Recover Right protocol

image376

 Impella RP Post-Approval Study Data Presented at ACC 2019

Mon March 18, 2019 7:00 AM|Business Wire|About: ABMD 

 NEW ORLEANS, La.--(BUSINESS WIRE)-- Abiomed (NASDAQ:ABMD) 


http://www.abiomed.com/impella/impella-rp

ZULRESSO™ (brexanolone) Injection

Data demonstrates survival benefit with the Impella RP Recover Right protocol

Data demonstrates survival benefit with the Impella RP Recover Right protocol

image377

Sage Therapeutics Announces FDA Approval of ZULRESSO™ (brexanolone) Injection, the First and Only Treatment Specifically Indicated for Postpartum Depression

Tue March 19, 2019 7:00 PM|Business Wire|About: SAGE 

seeking biotech alpha March 2019 insight

FARXIGA (dapagliflozin)

BRAFTOVI® (encorafenib) in Combination w/ MEKTOVI® (binimetinib) & ERBITUX® (cetuximab) panitumumab

BRAFTOVI® (encorafenib) in Combination w/ MEKTOVI® (binimetinib) & ERBITUX® (cetuximab) panitumumab

image378

First Sub-Analyses from the DECLARE-TIMI 58 Trial Further Support the Cardiovascular Effects of FARXIGA in Type 2 Diabetes

Mon March 18, 2019 9:01 AM|Business Wire|About: AZN 

BRAFTOVI® (encorafenib) in Combination w/ MEKTOVI® (binimetinib) & ERBITUX® (cetuximab) panitumumab

BRAFTOVI® (encorafenib) in Combination w/ MEKTOVI® (binimetinib) & ERBITUX® (cetuximab) panitumumab

BRAFTOVI® (encorafenib) in Combination w/ MEKTOVI® (binimetinib) & ERBITUX® (cetuximab) panitumumab

image379

BRAFTOVI® (encorafenib) in Combination with MEKTOVI® (binimetinib) and ERBITUX® (cetuximab) or panitumumab Recommended by the National Comprehensive Cancer Network® (NCCN) Guidelines as a Treatment Option for Patients with Advanced BRAF-mutant Colorectal Cancer

Mon March 18, 2019 8:00 AM|PR Newswire|About: ARRY

BOULDER, Colo., March 18, 2019 /PRNewswire/ -- Array BioPharma Inc. (ARRY


https://www.braftovimektovi.com/

(sNDA) for AVYCAZ® (ceftazidime and avibactam)

BRAFTOVI® (encorafenib) in Combination w/ MEKTOVI® (binimetinib) & ERBITUX® (cetuximab) panitumumab

(sNDA) for AVYCAZ® (ceftazidime and avibactam)

image380

Allergan Announces FDA Approval of AVYCAZ® (ceftazidime and avibactam) for Pediatric Patients

Mon March 18, 2019 7:30 AM|PR Newswire|About: AGNPR Newswire

DUBLIN, March 18, 2019 /PRNewswire/ -- Allergan plc (AGN)

Tecentriq® (atezolizumab)

saracatinib an Orphan Drug for the treatment of idiopathic pulmonary fibrosis (IPF).

(sNDA) for AVYCAZ® (ceftazidime and avibactam)

image381

FDA Approves Genentech’s Tecentriq in Combination With Chemotherapy for the Initial Treatment of Adults With Extensive-Stage Small Cell Lung Cancer

Mon March 18, 2019 9:15 PM|Business Wire|About: RHHBY 

(VENCLEXTA®/VENCLYXTO®) for the investigational treatment of multiple myeloma

saracatinib an Orphan Drug for the treatment of idiopathic pulmonary fibrosis (IPF).

saracatinib an Orphan Drug for the treatment of idiopathic pulmonary fibrosis (IPF).

image382

AbbVie Provides Update on VENCLEXTA®/VENCLYXTO® (venetoclax) Multiple Myeloma Program

Tue March 19, 2019 8:45 AM|PR Newswire|About: ABBV

NORTH CHICAGO, Ill., March 19, 2019 /PRNewswire/ -- AbbVie (ABBV)


https://www.venclexta.com/

saracatinib an Orphan Drug for the treatment of idiopathic pulmonary fibrosis (IPF).

saracatinib an Orphan Drug for the treatment of idiopathic pulmonary fibrosis (IPF).

saracatinib an Orphan Drug for the treatment of idiopathic pulmonary fibrosis (IPF).

image383

US FDA grants saracatinib Orphan Drug Designation for idiopathic pulmonary fibrosis  

18 March 2019 07:00 GMT

 AstraZeneca PLC (AZN) 

 

seeking biotech alpha March 2019 insight

LUMINIZE™ Radiofrequency (RF) Balloon Catheter

MitraClip™ for heart failure patients w/ clinically significant secondary or mitral regurgitation

MitraClip™ for heart failure patients w/ clinically significant secondary or mitral regurgitation

image384

 Late-breaking Clinical Trial Highlights Positive Safety and Efficacy Data for the LUMINIZE™ RF Balloon Catheter

Sun March 17, 2019 11:00 AM|PR Newswire|About: BSX 

Novocure (NVCR)

Stryker acquires OrthoSpace, Ltd.

Rubraca® (rucaparib)

image386

 Novocure to Participate in Oppenheimer’s 29th Annual Healthcare Conference

Mon March 18, 2019 7:30 AM|Business Wire|About: NVCR

ST. HELIER, Jersey--(BUSINESS WIRE)--

Novocure (NASDAQ:NVCR) 

Eliquis® (apixaban)

Stryker acquires OrthoSpace, Ltd.

Stryker acquires OrthoSpace, Ltd.

image387

AUGUSTUS Demonstrates Favorable Safety Results of Eliquis® Versus Vitamin K Antagonists in Non-Valvular Atrial Fibrillation Patients with Acute Coronary Syndrome and/or Undergoing Percutaneous Coronary Intervention

Sun March 17, 2019 11:45 AM|Business Wire|About: BMY, PFE 


https://www.eliquis.bmscustomerconnect.com/

Stryker acquires OrthoSpace, Ltd.

Stryker acquires OrthoSpace, Ltd.

Stryker acquires OrthoSpace, Ltd.

Stryker acquires OrthoSpace, Ltd.

03/14/2019

Kalamazoo, Michigan, March 14, 2019 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced today it has completed the acquisition of OrthoSpace, Ltd., a privately held company founded in 2009 and headquartered in Caesarea, Israel, in an all cash transaction for an upfront payment of $110 million and future milestone payments of up to an additional $110 million.

seeking biotech alpha March 2019 insight

MitraClip™ device used to repair a leaky mitral valve without open-heart surgery.

MitraClip™ device used to repair a leaky mitral valve without open-heart surgery.

MitraClip™ device used to repair a leaky mitral valve without open-heart surgery.

image388

Abbott Receives FDA Approval for Expanded Indication for MitraClip™ Device

Thu March 14, 2019 1:52 PM|PR Newswire|About: ABT 

Repatha® (evolocumab)

MitraClip™ device used to repair a leaky mitral valve without open-heart surgery.

MitraClip™ device used to repair a leaky mitral valve without open-heart surgery.

image389

Amgen Announces New Four-Year Outcomes Study To Examine Long-Term Effects Of Repatha® (evolocumab) In High-Risk Cardiovascular Disease (CVD) Patients Without Prior Heart Attack Or Stroke

Fri March 15, 2019 4:00 PM|PR Newswire|About: AMGN 

OPSUMIT® (macitentan)

da Vinci SP® surgical system for use in certain transoral otolaryngology procedures in adults.

OPSUMIT® (macitentan)

image391

 Interim Analysis Showed Treatment with OPSUMIT® (macitentan) Associated with Significant Improvement in Right Ventricular (RV) Function and Pulmonary Vascular Resistance (PVR) in Patients with Pulmonary Arterial Hypertension (PAH)

Fri March 15, 2019 9:00 AM|PR Newswire|About: JNJPR Newswire

SOUTH SAN FRANCISCO, Calif. and ALLSCHWIL, Switzerland, March 15, 2019 /PRNewswire/ -- Actelion Pharmaceuticals US, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson (JNJ)


https://www1.actelion.us/us/products/index.page?

da Vinci SP® surgical system for use in certain transoral otolaryngology procedures in adults.

da Vinci SP® surgical system for use in certain transoral otolaryngology procedures in adults.

da Vinci SP® surgical system for use in certain transoral otolaryngology procedures in adults.

image392

U.S. FDA Clears da Vinci SP for Certain Transoral Otolaryngology Procedures

Fri March 15, 2019 1:36 PM|GlobeNewswire|About: ISRGGlobeNewswire

SUNNYVALE, Calif., March 15, 2019 (GLOBE NEWSWIRE) -- Intuitive (ISRG)


https://www.intuitive.com/en-us/products-and-services/da-vinci/systems/sp

MabThera (rituximab) for a rare autoimmune disease

da Vinci SP® surgical system for use in certain transoral otolaryngology procedures in adults.

da Vinci SP® surgical system for use in certain transoral otolaryngology procedures in adults.

image393

 

Basel, 15 March 2019

European Commission approves Roche’s MabThera (rituximab) for a rare autoimmune disease

  • MabThera is the first biologic treatment approved for moderate to severe cases of the rare autoimmune disease pemphigus vulgaris (PV), and the first major advancement in the treatment of the disease in more than 60 years
  • PV is a rare and potentially life-threatening blistering condition which can cause severe pain and disfigurement
  • MabThera is now approved in Europe to treat four autoimmune diseases

Roche (SIX: RO, ROG; OTCQX: RHHBY)

seeking biotech alpha March 2019 insight

WATCHMAN FLX™ Left Atrial Appendage Closure (LAAC)

WATCHMAN FLX™ Left Atrial Appendage Closure (LAAC)

WATCHMAN FLX™ Left Atrial Appendage Closure (LAAC)

image394

Boston Scientific Receives CE Mark for Next Generation WATCHMAN FLX™ Left Atrial Appendage Closure Device

Wed March 13, 2019 7:00 AM|PR Newswire|About: BSXPR Newswire

MARLBOROUGH, Mass., March 13, 2019 /PRNewswire/ -- Boston Scientific Corporation (BSX

Praluent® (alirocumab)

WATCHMAN FLX™ Left Atrial Appendage Closure (LAAC)

WATCHMAN FLX™ Left Atrial Appendage Closure (LAAC)

image395

Regeneron and Sanofi to Present New Praluent® (alirocumab) Data at ACC.19

Wed March 13, 2019 7:00 AM|PR Newswire|About: REGN

TARRYTOWN, N.Y. and BRIDGEWATER, N.J., March 13, 2019 /PRNewswire/

Hemlibra® (emicizumab)

KEYTRUDA® (pembrolizumab) in Combination with Chemotherapy

Hemlibra® (emicizumab)

image397

Chugai’s Hemlibra Receives Approval for Severe Hemophilia A Without Factor VIII Inhibitors from the European Commission

Thu March 14, 2019 2:00 AM|Business Wire|About: CHGCY, RHHBY 

Venovo™ venous stent

KEYTRUDA® (pembrolizumab) in Combination with Chemotherapy

KEYTRUDA® (pembrolizumab) in Combination with Chemotherapy

image399

BD Receives U.S. FDA Approval for First Venous Stent to Treat Iliofemoral Venous Occlusive Disease

Thu March 14, 2019 6:59 AM|PR Newswire|About: BDXPR Newswire

FRANKLIN LAKES, N.J., March 14, 2019 /PRNewswire/ -- BD (Becton, Dickinson and Company (BDX)) (NYSE: BDX)

seeking biotech alpha March 2019 insight

Station B platform

Regeneron Pharmaceuticals, Inc. (REGN) and Society for Science & the Public

Regeneron Pharmaceuticals, Inc. (REGN) and Society for Science & the Public

image404

Princeton faculty to test new Microsoft Station B platform toward goal of boosting production of lifesaving biological therapies

by the Office of CommunicationsMarch 12, 2019 9:19 a.m. 


https://www.microsoft.com/en-us/research/project/stationb/

Regeneron Pharmaceuticals, Inc. (REGN) and Society for Science & the Public

Regeneron Pharmaceuticals, Inc. (REGN) and Society for Science & the Public

Regeneron Pharmaceuticals, Inc. (REGN) and Society for Science & the Public

image405

Teen Scientists Win $1.8 Million at Regeneron Science Talent Search 2019 with Innovative Ideas on Exoplanets, HIV and a Classic Math Problem

Tue March 12, 2019 9:56 PM|PR Newswire|About: REGN

TARRYTOWN, N.Y. and WASHINGTON, March 12, 2019 /PRNewswire/

seeking biotech alpha March 2019 insight

TRAZIMERA™ (trastuzumab-qyyp), a biosimilar to Herceptin® (trastuzumab)

TRAZIMERA™ (trastuzumab-qyyp), a biosimilar to Herceptin® (trastuzumab)

TRAZIMERA™ (trastuzumab-qyyp), a biosimilar to Herceptin® (trastuzumab)

image406

U.S. FDA Approves Pfizer’s Oncology Biosimilar TRAZIMERA™ (trastuzumab-qyyp), a Biosimilar to Herceptin®1

Mon March 11, 2019 7:37 PM|Business Wire|About: PFE

NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (PFE)

SYMDEKO® (tezacaftor/ivacaftor and ivacaftor)

TRAZIMERA™ (trastuzumab-qyyp), a biosimilar to Herceptin® (trastuzumab)

NBI-74788, a proprietary corticotropin-releasing factor type 1 (CRF1) receptor antagonist

image408

Vertex Receives Approval for SYMDEKO® (tezacaftor/ivacaftor and ivacaftor) in Australia, to Treat the Underlying Cause of Cystic Fibrosis in People aged 12 and Older with Certain CFTR Gene Mutations

Tue March 12, 2019 5:07 AM|Business Wire|About: VRTX 

Dupixent® (dupilumab) for adolescent patients 12 to 17 with moderate-to-severe atopic dermatitis

Dupixent® (dupilumab) for adolescent patients 12 to 17 with moderate-to-severe atopic dermatitis

Dupixent® (dupilumab) for adolescent patients 12 to 17 with moderate-to-severe atopic dermatitis

image410

FDA approves Dupixent® (dupilumab) for moderate-to-severe atopic dermatitis in adolescents

Mon March 11, 2019 3:45 PM|PR Newswire|About: REGN, SNY

* In a Phase 3 trial, Dupixent significantly reduced the extent and severity of disease and itching, and helped adolescents achieve clearer skin

PR Newswire

CAMBRIDGE, Mass. and TARRYTOWN, N.Y., March 11, 2019 /PRNewswire/

Station B

Dupixent® (dupilumab) for adolescent patients 12 to 17 with moderate-to-severe atopic dermatitis

Dupixent® (dupilumab) for adolescent patients 12 to 17 with moderate-to-severe atopic dermatitis

image411

 

Microsoft researchers have spent years studying those underlying processes and learning how to influence them. Now they are launching collaborations with Princeton University and UK-based companies Oxford Biomedica and Synthace to develop and test an integrated platform that’s designed to help other companies and research teams perform that work more reliably. The goal: To reduce the amount of trial and error required to make beneficial scientific breakthroughs and enable companies and academic researchers already established in the field to operate more efficiently and cost-effectively.

The project, called Station B, aims to develop an end-to-end platform — including a software stack, a means to automate lab experiments and machine learning methods that run in the cloud on Microsoft Azure — to help scientists more efficiently and predictably channel the power of life’s ultimate information processing machines: living cells.

 

Jennifer Langston

Mar 11, 2019

CAMBRIDGE, United Kingdom – In recent years, companies have figured out how to engineer bacteria to make cement, helping reduce the pollution involved in traditional manufacturing. Using more advanced techniques, scientists have even programmed patients’ immune cells to recognize and kill leukemia cells, giving children who had virtually no chance of survival years of prolonged life.

seeking biotech alpha March 2019 insight

Bristol-Myers Squibb C... (BMY)

Tecentriq® (atezolizumab) plus chemo (Abraxane® [paclitaxel protein-bound particles for injectable

Tecentriq® (atezolizumab) plus chemo (Abraxane® [paclitaxel protein-bound particles for injectable

image412

Bristol-Myers sends open letter to shareholders supporting rationale for Celgene merger

Mar. 6, 2019 7:17 AM ET|About: Bristol-Myers Squibb C... (BMY)|By: , SA News Editor  


https://news.bms.com/press-release/corporatefinancial-news/bristol-myers-squibb-files-investor-presentation-and-board-dir

Tecentriq® (atezolizumab) plus chemo (Abraxane® [paclitaxel protein-bound particles for injectable

Tecentriq® (atezolizumab) plus chemo (Abraxane® [paclitaxel protein-bound particles for injectable

Tecentriq® (atezolizumab) plus chemo (Abraxane® [paclitaxel protein-bound particles for injectable

image413

FDA Grants Genentech’s Tecentriq in Combination With Abraxane Accelerated Approval for People With PD-L1-Positive, Metastatic Triple-Negative Breast Cancer

Fri March 8, 2019 12:06 PM|Business Wire|About: RHHBY 


https://www.abraxane.com/

https://www.tecentriq-hcp.com/

Medtronic plc (MDT)

Tecentriq® (atezolizumab) plus chemo (Abraxane® [paclitaxel protein-bound particles for injectable

Ozanimod is an oral, sphingosine 1-phosphate (S1P) receptor modulator

image414

Medtronic Announces Cash Dividend for Fourth Quarter of Fiscal Year 2019

Fri March 8, 2019 4:30 PM|InPublic US|About: MDT


Board Authorizes $6 Billion for Share Repurchases

DUBLIN - March 8, 2018 - The board of directors of Medtronic plc (MDT)

Ozanimod is an oral, sphingosine 1-phosphate (S1P) receptor modulator

Ozanimod is an oral, sphingosine 1-phosphate (S1P) receptor modulator

Ozanimod is an oral, sphingosine 1-phosphate (S1P) receptor modulator

image415

Celgene Submits Application to EMA for Ozanimod for the Treatment of Relapsing-Remitting Multiple Sclerosis

Mon March 11, 2019 7:30 AM|Business Wire|About: CELG

New Drug Application submission to U.S. FDA on track for end of March

SUMMIT, N.J.--(BUSINESS WIRE)-- Celgene Corporation (CELG)

ubrogepant for the acute treatment of migraine in adults.

Ozanimod is an oral, sphingosine 1-phosphate (S1P) receptor modulator

ubrogepant for the acute treatment of migraine in adults.

image416

Allergan Announces FDA Acceptance of New Drug Application for Ubrogepant for the Acute Treatment of Migraine

Mon March 11, 2019 7:30 AM|PR Newswire|About: AGN

Allergan Continues to Expand Its Leading Migraine Portfolio Across the Spectrum of the Disease from Episodic to Chronic -

PR Newswire

DUBLIN, March 11, 2019 /PRNewswire/ -- Allergan plc (AGN)

seeking biotech alpha March 2019 insight

GS-6207, a novel, selective, first-in-class inhibitor of HIV-1 capsid function

Tecentriq (atezolizumab), combined with Avastin (bevacizumab) and chemo paclitaxel and carboplatin

GS-6207, a novel, selective, first-in-class inhibitor of HIV-1 capsid function

image418

 Gilead Announces Data From Two Studies Supporting Further Development of GS-6207, a Novel, Investigational HIV-1 Capsid Inhibitor as a Component of Future Long-Acting HIV Therapies

Thu March 7, 2019 5:30 PM|Business Wire|About: GILD

FOSTER CITY, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (GILD)

Dupixent® (dupilumab)

Tecentriq (atezolizumab), combined with Avastin (bevacizumab) and chemo paclitaxel and carboplatin

GS-6207, a novel, selective, first-in-class inhibitor of HIV-1 capsid function

image419

FDA to Undertake Priority Review of Dupixent® (dupilumab) for Adults with Inadequately Controlled Severe Chronic Rhinosinusitis with Nasal Polyps

Fri March 8, 2019 12:59 AM|PR Newswire|About: REGN

TARRYTOWN, N.Y. and PARIS, March 8, 2019 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (REGN) and Sanofi

zinc finger nuclease (ZFN) platform technology

darolutamide, a non-steroidal androgen receptor antagonist

Tecentriq (atezolizumab), combined with Avastin (bevacizumab) and chemo paclitaxel and carboplatin

image421

Sangamo Therapeutics Announces Publication Of Data Demonstrating New Zinc Finger Nuclease Architectures Enabling High-Precision Genome Editing

Fri March 8, 2019 5:00 AM|PR Newswire|About: SGMO 

SOLIRIS® (Eculizumab)

darolutamide, a non-steroidal androgen receptor antagonist

darolutamide, a non-steroidal androgen receptor antagonist

image423

Alexion Announces Publication of Interim Data from Phase 3 Open-Label Extension Study Supporting Long-Term Efficacy and Safety of SOLIRIS® (Eculizumab) in Adult Patients with Generalized Myasthenia Gravis in Muscle & Nerve

Fri March 8, 2019 9:05 AM|Business Wire|About: ALXN